封面
市場調查報告書
商品編碼
1138301

全球抗癌藥物市場-2022-2029

Global Cancer Treatment Drugs Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

政府和私人組織激活教育活動有望成為市場增長的驅動力

政府和私人組織的宣傳計劃有助於提高人們對診斷乳腺癌的認識並推動市場增長。對乳腺癌的認識很低,女性不願談論這種感染。許多政府發起的宣傳計劃有助於提高乳腺癌的診斷率。因此,早期診斷乳腺癌有助於提高治愈乳腺癌的機會。它還在預測期內為市場做出了貢獻,因為治療也可以更有效地提供。 NBCF(國家乳腺癌基金會)通過為美國和其他國家/地區的女性提供免費的乳房 X 光檢查以及在國家乳房 X 線攝影計劃下提供免費的乳腺癌教育來幫助世界各地的人們。該組織提供有關乳腺癌的重要資源,並通過對女性進行有關身體的教育,使她們能夠控制自己的健康。包括個人培訓課程、活動材料、在線培訓模塊等。 NCBF 與其他組織合作,為全國社區的女性提供乳腺癌教育和早期檢測。

此外,癌症治療研究和開發正在推動預測期內的市場增長。例如,2020 年 7 月,美國國家癌症研究所 (NCI) 資助了一項關於胰腺癌的高級研究計劃,以促進我們對預防、檢測和治療的理解。胰腺癌比其他類型的癌症更難早期發現,並且通常在晚期被診斷出來。這項資助的胰腺癌研究包括測試早期和晚期胰腺癌的治療方法。

全球腫瘤藥物市場報告提供了大約 53 個市場數據表、47 個數字和 170 頁的結構。

內容

第一章調查方法及範圍

  • 調查方法
  • 市場範圍

第 2 章主要趨勢和發展

第 3 章執行摘要

  • 按藥物類別劃分的市場細分
  • 按指標劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
    • 約束因素
    • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措

第 7 章按藥物類別類型

  • 化療
  • 靶向藥物
  • 免疫療法
  • 激素療法

第 8 章適應症

  • 肺癌
  • 肝癌
  • 乳腺癌
  • 膀胱癌
  • 結腸癌
  • 前列腺癌
  • 胃癌

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 競爭對手戰略分析
  • 市場情況/份額分析
  • 併購分析

第 11 章公司簡介

  • AbbVie, Inc
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene
  • CARsgen Therapeutics
  • CStone Pharmaceuticals Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics
  • Legend Biotech Co.

第12章 DataM

簡介目錄
Product Code: DMHCIT2955

Market Overview

Cancer treatment drugs market was valued at USD 153.23 million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 10.6% during the forecast period (2022-2029).

The widespread prevalence of cancer leads to the rapid development of cancer treatment drugs. Various drugs have received regulatory approval from the USFDA (Food and Drug Administration) the cancer treatment. The leading pharmaceutical and biotechnology companies are developing their cancer research, considering the disease's rising global burden. The increasing cancer population worldwide due to the demand for cancer treatment drugs drives the market growth. Also, government involvement in raising awareness regarding cancer symptoms and their early diagnosis further contributes to the global market growth.

Market Dynamics: Increasing awareness programs by government and private organizations are expected to drive market growth.

Awareness programs by government and private organizations help to increase the awareness of the diagnosis in people for breast cancer which helps to drive market growth. There was less awareness about breast cancer; women hesitated to discuss that type of infection. The number of awareness programs by government initiatives helps to improve the breast cancer diagnosis rate; thus, early diagnosis of breast cancer helps to improve the chances of curing breast cancer. Also, the treatment can be more effective, which helps the market in the forecast period. The NBCF, National Breast Cancer Foundation, provides free mammograms to women across the US and other countries under the national mammography program and hands to help people worldwide by providing free breast cancer education. This organization provides important breast cancer resources and empowers women to control their health by educating them about their bodies. It includes personal training sessions, event material, and online training modules. The NCBF has partnered with other organizations to provide breast cancer education and early detection of breast cancer to women in the community across the country.

Moreover, the research and development in cancer treatment are boosting the market growth during the forecast period. For instance, in July 2020, National Cancer Institute (NCI) funded an advanced research program on pancreatic cancer to advance the understanding of prevention, detection, and treatment. Pancreatic cancer is hard to detect early compared to other types of cancers and is often diagnosed at an advanced stage. This funded research for pancreatic cancer includes testing treatments for early-stage pancreatic cancer and advanced pancreatic cancer treatments.

Market Segmentation: The chemotherapy segment accounted for the highest share in global cancer treatment drugs market.

Chemotherapy is the most widely used treatment for cancer which destroys and reduces cancer-growing cells. Systemic chemotherapy grows into the bloodstream to spread cancer cells throughout the body. Some of the most common ways of chemotherapy are an intravenous tube placed into a vein using a needle, an injection under the skin or into a muscle (intramuscular), and swallowing the drug and capsule. There are two types of chemotherapy such as adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy destroys cancer cell spread and is not seen by imaging tests. The adjuvant chemotherapy reduces the cancer cells that form new tumors in the other place of the body.

Furthermore, breast cancer is expected to dominate the cancer treatment drugs market during the forecast period. The high prevalence of breast cancer in women worldwide drives the market. Most breast cancer begins either in the breast tissue made up of glands for milk production, called lobules or in the ducts that connect the lobules to the nipple. Breast cancer is the most common cancer in women in the developed and developing world. Breast cancer cases are increasing in developing countries due to reproductive, menstrual, and lifestyle changes. According to the World Health Organization report published in 2020, breast cancer has the largest number of new cases in 2020, estimated at 11.7% of the total new cases estimated during the year. Around 2.3 million new breast cancer cases were registered globally in 2020, with a mortality rate of about 685,000. Therefore, the expenditure on breast cancer therapies and medicines is increasing rapidly, which leads to the high diagnosis and treatment of breast cancer worldwide.

Geographical Penetration: North America is the dominating region during the forecast period.

North American region dominated the global cancer treatment drugs market and accounted for the largest market share. The well-developed healthcare infrastructure and key market players, such as Pfizer Inc., Merck & Co., Inc., and Johnson & Johnson Services, Inc., are factors driving the region's market growth. In North America, the US contributed the major share of around 85.0% in the regional market growth. Besides, Canada is expected to project a considerable CAGR in the regional market during the forecast period.

Additionally, high healthcare spending costs have been the primary reason for the growth of the market. As per the World Bank data, the US's disposable income was recorded as $10,350. Their national health expenditure was $3.3 trillion, promoting healthcare services usage and motivating the cancer treatment drugs market. The US Government has included various diagnostic tools to search for any indicative breast cancer symptoms to control and manage the disease. Besides, the public and private organizations have many reimbursement policies for lessening the financial burden arising due to the disease. Many organizations, such as the American Cancer Society, guide women who have breast cancer.

Competitive Landscape:

The cancer treatment drugs market is fragmented due to multiple companies' availability. Some of the major key players in the market are AbbVie, Inc., AstraZeneca PLC, Bayer AG, BeiGene, CARsgen Therapeutics, CStone Pharmaceuticals Co., Ltd. and GlaxoSmithKline PLC, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the cancer treatment drugs market globally. In July 2020, AstraZeneca and Merck & Co., Inc. announced that Lynparza (olaparib) had been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. This approval further provides the company with a significant opportunity to sustain a substantial European pancreatic cancer drugs market position. In June 2020, AbbVie collaborated with Jacobio Pharmaceuticals to develop and commercialize SHP2 inhibitors that act on an important node in cancer and immune cells. In January 2022, AbbVie Announced U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for the treatment of non-small cell lung cancer. In October 2021, US FDA approved Roche's Tecentriq as an adjuvant treatment for people with early non-small cell lung cancer. It is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

COVID-19 Impact: Negative impact on the global cancer treatment drugs market

The outbreak of the COVID-19 pandemic will harm the growth of the cancer treatment market in 2020. It has significantly affected oncology clinical research due to the increasing focus on clinical research for COVID-19 treatment. A large number of oncology trials were suspended due to the COVID-19 pandemic. It has also affected the enrollment of patients in oncology clinical trials in the US and Europe. Therefore, a modest decline in the cancer treatment market is estimated in 2020; however, the market is expected to regain growth in the third quarter of 2021

The global cancer treatment drugs market report would provide an access to approximately 53 market data tables, 47 figures and 170 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Drug Class Type
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Drug Class Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Class Type Segment
    • 7.1.2. Market attractiveness index, By Drug Class Type Segment
  • 7.2. Chemotherapy *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Targeted Therapy
  • 7.4. Immunotherapy
  • 7.5. Hormonal Therapy

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Indication Segment
    • 8.1.2. Market attractiveness index, By Indication Segment
  • 8.2. Lung Cancer *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Liver Cancer
  • 8.4. Breast Cancer
  • 8.5. Bladder Cancer
  • 8.6. Colorectal Cancer
  • 8.7. Prostate Cancer
  • 8.8. Stomach Cancer

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Type.
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. AbbVie, Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. AstraZeneca PLC
  • 11.3. Bayer AG
  • 11.4. BeiGene
  • 11.5. CARsgen Therapeutics
  • 11.6. CStone Pharmaceuticals Co., Ltd.
  • 11.7. GlaxoSmithKline PLC
  • 11.8. Johnson & Johnson Services, Inc.
  • 11.9. JW Therapeutics
  • 11.10. Legend Biotech Co.
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us